-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinnet.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
.
.
At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
Data source: official website of the State Food and Drug Administration, Mynet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinnet.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
.
.
At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
Data source: official website of the State Food and Drug Administration, Mynet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
.
According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
.
Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
.
The product was approved by the U.
S.
FDA in 2010 and approved for listing in China in 2019.
In 2020, its global sales reached 194.
2 billion yen (approximately 1.
7 billion U.
S.
dollars)
.
Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinnet.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
.
Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
.
.
At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
Enterprise business enterprise.
In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
The same comment
.
A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
.
In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
.
Data source: official website of the State Food and Drug Administration, Mynet database
Data source: official website of the State Food and Drug Administration, Mynet database Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Pharmacy pharmacy pharmacy .
The above sales are calculated based on the average retail price of the product at the terminal
.
